Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma

A Comparative Study

Youngseok Lee, Youngjoon Ryu, Hoiseon Jeong, Hyeyoon Chang, Younghye Kim, Aeree Kim

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Background and Aims: HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis. Recently, a new direct evaluation technique, silver enhanced in situ hybridization (SISH) was developed for evaluating HER2 gene status. This study was performed to evaluate the SISH technique for clinical use by comparing it to that of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods: We studied 543 cases of excised breast specimens diagnosed as invasive ductal carcinoma by IHC, FISH, and SISH using a tissue microarray. IHC, FISH, and SISH results were interpreted according to the American Society of Clinical Oncology/College of American Pathologists guidelines. A total of seven English studies that reported the concordance rates of SISH and BDISH compared to FISH published before July 2011 were retrieved. Results: The consensus concordance rate between SISH and FISH was 96.69% (kappa value = 0.9175). The pooled sensitivity was 0.94 [95% confidence interval (CI) = 0.91-0.97], and the pooled specificity was 0.98 (95% CI = 0.96-099) in a meta-analysis of the retrieved studies and this study. Area under the receiver operating characteristics curve was 0.9906. Conclusions: SISH technique is an effective modality and is comparable with FISH for evaluating HER2 gene amplification in patients with breast carcinoma.

Original languageEnglish
Pages (from-to)139-144
Number of pages6
JournalArchives of Medical Research
Volume43
Issue number2
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

erbB-2 Genes
Silver
In Situ Hybridization
Fluorescence In Situ Hybridization
Breast Neoplasms
Gene Amplification
Immunohistochemistry
Confidence Intervals
Ductal Carcinoma
ROC Curve
Meta-Analysis
Breast
Guidelines

Keywords

  • ErbB-2
  • Fluorescence in situ hybridization
  • HER2
  • Meta-analysis
  • Silver in situ hybridization

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma : A Comparative Study. / Lee, Youngseok; Ryu, Youngjoon; Jeong, Hoiseon; Chang, Hyeyoon; Kim, Younghye; Kim, Aeree.

In: Archives of Medical Research, Vol. 43, No. 2, 01.02.2012, p. 139-144.

Research output: Contribution to journalArticle

Lee, Youngseok ; Ryu, Youngjoon ; Jeong, Hoiseon ; Chang, Hyeyoon ; Kim, Younghye ; Kim, Aeree. / Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma : A Comparative Study. In: Archives of Medical Research. 2012 ; Vol. 43, No. 2. pp. 139-144.
@article{a8b941d14f7c424a820086d7d6a02abf,
title = "Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma: A Comparative Study",
abstract = "Background and Aims: HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis. Recently, a new direct evaluation technique, silver enhanced in situ hybridization (SISH) was developed for evaluating HER2 gene status. This study was performed to evaluate the SISH technique for clinical use by comparing it to that of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods: We studied 543 cases of excised breast specimens diagnosed as invasive ductal carcinoma by IHC, FISH, and SISH using a tissue microarray. IHC, FISH, and SISH results were interpreted according to the American Society of Clinical Oncology/College of American Pathologists guidelines. A total of seven English studies that reported the concordance rates of SISH and BDISH compared to FISH published before July 2011 were retrieved. Results: The consensus concordance rate between SISH and FISH was 96.69{\%} (kappa value = 0.9175). The pooled sensitivity was 0.94 [95{\%} confidence interval (CI) = 0.91-0.97], and the pooled specificity was 0.98 (95{\%} CI = 0.96-099) in a meta-analysis of the retrieved studies and this study. Area under the receiver operating characteristics curve was 0.9906. Conclusions: SISH technique is an effective modality and is comparable with FISH for evaluating HER2 gene amplification in patients with breast carcinoma.",
keywords = "ErbB-2, Fluorescence in situ hybridization, HER2, Meta-analysis, Silver in situ hybridization",
author = "Youngseok Lee and Youngjoon Ryu and Hoiseon Jeong and Hyeyoon Chang and Younghye Kim and Aeree Kim",
year = "2012",
month = "2",
day = "1",
doi = "10.1016/j.arcmed.2012.03.010",
language = "English",
volume = "43",
pages = "139--144",
journal = "Archives of Medical Research",
issn = "0188-4409",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Effectiveness of Silver-enhanced In Situ Hybridization for Evaluating HER2 Gene Status in Invasive Breast Carcinoma

T2 - A Comparative Study

AU - Lee, Youngseok

AU - Ryu, Youngjoon

AU - Jeong, Hoiseon

AU - Chang, Hyeyoon

AU - Kim, Younghye

AU - Kim, Aeree

PY - 2012/2/1

Y1 - 2012/2/1

N2 - Background and Aims: HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis. Recently, a new direct evaluation technique, silver enhanced in situ hybridization (SISH) was developed for evaluating HER2 gene status. This study was performed to evaluate the SISH technique for clinical use by comparing it to that of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods: We studied 543 cases of excised breast specimens diagnosed as invasive ductal carcinoma by IHC, FISH, and SISH using a tissue microarray. IHC, FISH, and SISH results were interpreted according to the American Society of Clinical Oncology/College of American Pathologists guidelines. A total of seven English studies that reported the concordance rates of SISH and BDISH compared to FISH published before July 2011 were retrieved. Results: The consensus concordance rate between SISH and FISH was 96.69% (kappa value = 0.9175). The pooled sensitivity was 0.94 [95% confidence interval (CI) = 0.91-0.97], and the pooled specificity was 0.98 (95% CI = 0.96-099) in a meta-analysis of the retrieved studies and this study. Area under the receiver operating characteristics curve was 0.9906. Conclusions: SISH technique is an effective modality and is comparable with FISH for evaluating HER2 gene amplification in patients with breast carcinoma.

AB - Background and Aims: HER2 gene amplification occurs in breast cancers and has implications for treatment and prognosis. Recently, a new direct evaluation technique, silver enhanced in situ hybridization (SISH) was developed for evaluating HER2 gene status. This study was performed to evaluate the SISH technique for clinical use by comparing it to that of fluorescence in situ hybridization (FISH) and immunohistochemistry (IHC). Methods: We studied 543 cases of excised breast specimens diagnosed as invasive ductal carcinoma by IHC, FISH, and SISH using a tissue microarray. IHC, FISH, and SISH results were interpreted according to the American Society of Clinical Oncology/College of American Pathologists guidelines. A total of seven English studies that reported the concordance rates of SISH and BDISH compared to FISH published before July 2011 were retrieved. Results: The consensus concordance rate between SISH and FISH was 96.69% (kappa value = 0.9175). The pooled sensitivity was 0.94 [95% confidence interval (CI) = 0.91-0.97], and the pooled specificity was 0.98 (95% CI = 0.96-099) in a meta-analysis of the retrieved studies and this study. Area under the receiver operating characteristics curve was 0.9906. Conclusions: SISH technique is an effective modality and is comparable with FISH for evaluating HER2 gene amplification in patients with breast carcinoma.

KW - ErbB-2

KW - Fluorescence in situ hybridization

KW - HER2

KW - Meta-analysis

KW - Silver in situ hybridization

UR - http://www.scopus.com/inward/record.url?scp=84860615525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860615525&partnerID=8YFLogxK

U2 - 10.1016/j.arcmed.2012.03.010

DO - 10.1016/j.arcmed.2012.03.010

M3 - Article

VL - 43

SP - 139

EP - 144

JO - Archives of Medical Research

JF - Archives of Medical Research

SN - 0188-4409

IS - 2

ER -